Basant Farag | Drug Discovery and Development | Best Researcher Award

Dr. Basant Farag | Drug Discovery and Development | Best Researcher Award

Zagazig University Faculty of Science | Egypt

Dr. Basant Farag is a distinguished organic chemist and assistant lecturer at the Department of Chemistry, Faculty of Science, Zagazig University, Egypt, with extensive expertise in the synthesis, biological evaluation, and computational studies of heterocyclic compounds. She completed her Ph.D. in Organic Chemistry at Zagazig University, building on her M.Sc. and B.Sc. degrees in the same field, demonstrating a consistent commitment to advancing chemical sciences. Her academic career encompasses teaching, mentoring students, and conducting cutting-edge research while serving as a teaching assistant and assistant lecturer, preparing lectures, evaluating students, and engaging in independent research projects. Dr. Farag is also an accomplished international reviewer for numerous journals including Chemistry Select, Eurasian Journal of Chemistry, Journal of Molecular Structure, Bioorganic Chemistry, and International Journal of Biological Macromolecules, highlighting her broad expertise and recognition in the global scientific community.Her research portfolio includes pioneering studies in the design and synthesis of biologically active heterocyclic compounds, focusing on pharmacologically relevant molecules with anticancer, antimicrobial, and antitubercular properties. Her notable publications include Synthesis and Molecular Docking of Some Novel 3-Thiazolyl-Coumarins as Inhibitors of VEGFR-2 Kinase, Mechanochemical Synthesis and Molecular Docking Studies of New Azines Bearing Indole as Anticancer Agents, Green Synthesis and Molecular Docking Study of Some New Thiazoles Using Terephthalohydrazide Chitosan Hydrogel as Ecofriendly Biopolymeric Catalyst, Green Route Synthesis and Molecular Docking of Azines Using Cellulose Sulfuric Acid under Microwave Irradiation, Synthesis, Molecular Docking and Anticancer Activity of Some 5-Aryl-5,10-Dihydropyrido[2,3-d:6,5-d′]Dipyrimidine-2,4,6,8-Tetraone Derivatives and Pyrido[2,3-d], Synthesis, Molecular Docking Study, and Biological Evaluation of New Thiadiazole and Thiazole Derivatives Incorporating Isoindoline-1,3-Dione Moiety as Anticancer and Antimicrobial Agents, Green Biocatalyst for Ultrasound-Assisted Thiazole Derivatives: Synthesis, Antibacterial Evaluation, and Docking Analysis, Cyanauric Chloride as a Key Precursor and a Core Component for Three-Armed Triazolopyrimidines: Recent Finding About SARs and Docking Analyses, Chitosan–Sulfonic Acid-Catalyzed Green Synthesis of Naphthalene-Based Azines as Potential Anticancer Agents, Synthesis, Molecular Docking, In Silico Study, and Evaluation of Bis-Thiazole-Based Curcumin Derivatives as Potential Antimicrobial Agents, and Design and Synthesis of Novel Hybrids Incorporating Thiadiazole or Thiazole-Naphthalene: Anticancer Assessment and Molecular Docking Study.

Profile: Google Scholar

Featured Publications

Abolibda, T. Z., Fathalla, M., Farag, B., Zaki, M. E. A., & Gomha, S. M. (n.d.). Synthesis and molecular docking of some novel 3-thiazolyl-coumarins as inhibitors of VEGFR-2 kinase. Molecules.

Ibrahim, M. S., Farag, B., Al-Humaidi, J. Y., Zaki, M. E. A., Fathalla, M., & Gomha, S. M. (n.d.). Mechanochemical synthesis and molecular docking studies of new azines bearing indole as anticancer agents. Molecules.

Gomha, S. M., Riyadh, S. M., Alharbi, R. A. K., Zaki, M. E. A., Abolibda, T. Z., & Farag, B. (n.d.). Green route synthesis and molecular docking of azines using cellulose sulfuric acid under microwave irradiation. Crystals.

Al-Humaidi, J. Y., Gomha, S. M., El-Ghany, N. A. A., Farag, B., Zaki, M. E. A., et al. (n.d.). Green synthesis and molecular docking study of some new thiazoles using terephthalohydrazide chitosan hydrogel as ecofriendly biopolymeric catalyst. Catalysts.

Hussein, A. M., Gomha, S. M., El-Ghany, N. A. A., Zaki, M. E. A., Farag, B., et al. (n.d.). Green biocatalyst for ultrasound-assisted thiazole derivatives: Synthesis, antibacterial evaluation, and docking analysis. ACS Omega.

Mokbel, W. A., Hosny, M. A., Gomha, S. M., Zaki, M. E. A., Farag, B., El Farargy, A. F., et al. (n.d.). Synthesis, molecular docking study, and biological evaluation of new thiadiazole and thiazole derivatives incorporating isoindoline-1,3-dione moiety as anticancer and antimicrobial agents. Results in Chemistry.

Gaetan Ligat | Drug Discovery and Development | Best Researcher Award

Assoc. Prof. Dr. Gaetan Ligat | Drug Discovery and Development | Best Researcher Award

Assoc. Prof. Dr. Gaetan Ligat at Toulouse University | France

Assoc. Prof. Dr. Gaetan Ligat is a molecular virologist and principal investigator at Toulouse University, affiliated with INSERM UMR1291 and CNRS UMR5051. He leads the ViNeDys team at the Toulouse Institute for Infectious and Inflammatory Diseases, focusing on host–human cytomegalovirus interactions in brain tumors and therapeutic innovation. With extensive research and teaching experience across France, he has contributed to advancing antiviral strategies, mentoring young scientists, and promoting scientific communication. He is actively engaged in international collaborations, scientific societies, and community outreach, while securing multiple research grants to strengthen translational virology and oncology research.

Publication Profile 

Google Scholar

Education 

Assoc. Prof. Dr. Gaetan Ligat pursued his scientific training at Limoges University, France. He earned a Master of Science degree in Genetics and Physiology, which laid the foundation for his research career. He then advanced to doctoral studies at INSERM UMR1092, Limoges University, where he specialized in Molecular Virology, completing his PhD with distinction. His academic formation emphasized molecular biology, virus-host interactions, and translational virology, providing expertise in genetics, physiology, and applied biomedical sciences. This strong educational background enabled him to develop a career bridging fundamental research and therapeutic applications, particularly in virology, cancer biology, and innovative antiviral treatment strategies.

Experience 

Assoc. Prof. Dr. Gaetan Ligat is Associate Professor of Virology at Toulouse University, where he also serves as Principal Investigator and group leader of the ViNeDys team at the Infinity Institute. His work focuses on host–HCMV interactions and therapeutic innovation in brain tumors. Previously, he was a postdoctoral researcher at INSERM UMR1110 in Strasbourg, specializing in antiviral strategies. He began his research as a Master’s and PhD candidate at INSERM UMR1092, Limoges. Alongside research, he has coordinated training programs, practical courses, and supervised over 20 students. He is deeply involved in scientific societies, equality initiatives, and international collaborations.

Awards and Honors 

Assoc. Prof. Dr. Gaetan Ligat has received numerous prestigious recognitions, including the National Thesis Prize from the French Society of Microbiology and fellowships from the French National Agency for Research on AIDS and Viral Hepatitis (ANRS). He was awarded an ESCMID Research Grant, travel grants from the French Society of Microbiology, and registration bursaries for international congresses. His successful fundraising as principal investigator includes support from cancer foundations, patient associations, and Inserm/Regional PhD funding. These honors reflect both his scientific excellence and commitment to translational virology and oncology research. His awards highlight his impact on advancing antiviral and therapeutic research.

Research Focus 

Assoc. Prof. Dr. Gaetan Ligat research focuses on the molecular biology of human cytomegalovirus (HCMV) and its interaction with host cells, particularly in brain tumor environments. His work aims to understand how viral mechanisms contribute to disease progression and to identify novel therapeutic targets. He develops innovative antiviral strategies, including peptides and antibodies targeting HCMV protein interactions. His research also explores inflammatory responses, host-pathogen dynamics, and translational approaches for cancer treatment. Through collaborative projects and funded research programs, he seeks to bridge fundamental virology with therapeutic innovation, advancing the fight against viral infections and HCMV-related diseases in oncology.

Publication Top Notes

The human cytomegalovirus terminase complex as an antiviral target: a close-up view

Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives

Hepatitis C virus (HCV)–apolipoprotein interactions and immune evasion and their impact on HCV vaccine design

Hepatitis B virus–host interactions and novel targets for viral cure

Hepatitis B virus core variants, liver fibrosis, and hepatocellular carcinoma

Targeting viral cccDNA for cure of chronic hepatitis B

The Yin and the Yang of extracellular vesicles during viral infections

Structures and divergent mechanisms in capsid maturation and stabilization following genome packaging of human cytomegalovirus and herpesviruses

Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: benefits and limits of 3D analysis

Interferon‐Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection

Identification of a short sequence in the HCMV terminase pUL56 essential for interaction with pUL89 subunit

Identification of amino acids essential for viral replication in the HCMV helicase-primase complex